Abstract
This article reviews the use of white-matter changes as identified on MRI as a surrogate marker in clinical trials on vascular dementia. As of yet, insufficient evidence is present to implement rating or volumetric assessment of the burden of white-matter changes as surrogate marker in such trials, in view of the limited sensitivity to change of current methods and the high measurement error.
| Original language | English |
|---|---|
| Pages (from-to) | 261-265 |
| Number of pages | 5 |
| Journal | International Psychogeriatrics |
| Volume | 15 |
| Issue number | SUPPL. 1 |
| DOIs | |
| Publication status | Published - 7 Oct 2003 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Clinical trials
- Dementia
- MRI
- pH
- Vascular
- White matter
Fingerprint
Dive into the research topics of 'White-matter changes on MRI as surrogate marker'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver